Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung

Cancer Science

Volumn 100, Issue 2, 2009, Pages 249-254

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Imai, Hisao ^a   Shimizu, Kimihiro ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Hisada, Takeshi ^a   Ishizuka, Tamotsu ^a   Kanai, Yoshikatsu ^a   Endou, Hitoshi ^b   Nakajima, Takashi ^c   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD98 ANTIGEN; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; AMINO ACID TRANSPORTER; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR VASCULARIZATION; CANCER INVASION; ENZYME IMMUNOASSAY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD98; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 58549111213     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01029.x     Document Type: Article

References (33)

1. Travis WD, Colby TV, Corrin B. Histological Typing of Lung and Pleural Tumors, World Health Organization, International Histological Classification of Tumors, 3rd edn. Berlin: Spring-Verlag, 1999: 29.
2. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
3. McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 1994; 299: 321-34.
4. Oxender DL, Christensen HN. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 1963; 197: 765-7.
5. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
6. Kaira K, Oriuchi N, Imai H et al. Expression of 1-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008; 204: 553-61.
7. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Seminars Cancer Biol 2006; 15: 254-66.
8. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of 1-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98: 742-8.
9. Kaira K, Oriuchi N, Otani Y et al. Fluorine-18-α-Methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A clinicopathological study. Clin Cancer Res 2007; 13: 6369-78.
10. Mountain CF. Revision in the international System for staging lung cancer. Chest 1997; 11: 1710-17.
11. Yanagida O, Kanai Y, Chairoungdua A et al. Human 1-type amino acid transporter 1 (LAT 1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
12. Chairoungdua A, Segawa H, Kim JY et al. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 1999; 274: 28845-8.
13. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-92.
14. Matsuo H, Tsukada S, Nakata T et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 2000; 11: 3507-11.
15. Buck AC, Schirrmeister HH, Guhlmann CA et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: Does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42: 721-5.
16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
17. Oda Y, Yamamoto H, Tamiya S et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Modern Pathol 2006; 19: 738-45.
18. Nakanishi K, Ogata S, Matsuo H et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007; 451: 681-90.
19. Rintoul RC, Buttery RC, Mackinnon AC et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002; 13: 2841-52.
20. Takeuchi H, Kubota T, Kitai R, Nakagawa T, Hashimoto N. CD98 immunoreactivity in multinucleated giant cells of glioblastomas: An immunohistochemical double labeling study. Neuropathology 2008; 28: 127-31.
21. Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of 1-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2 hc) in liver tumor lesions of rat models. J Surg Oncol 2001; 78: 265-71; discussion 271-2.
22. Martin B, Paesmans M, Mascaux C et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer 2004; 91: 2018-25.
23. Imoto H, Osaki T, Taga S et al. Vascular endothelial growth factor expression in non-small cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007-14.
24. Han H, Silverman JF, Santucci TS et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001; 8: 72-9.
25. Oriuchi N, Higuchi T, Ishikita T et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 2006; 97: 1291-7.
26. Kaira K, Oriuchi N, Otani Y et al. Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with 18 F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131: 1019-27.
27. Inoue T, Koyama K, Oriuchi N et al. Detection of malignant tumors: whole-body PET with fluorine-18-α-methyl tyrosine versus FDG-preliminary study. Radiology 2001; 220: 54-62.
28. Kim DK, Kanai Y, Choi HW et al. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 2002; 1565: 112-22.
29. Winton T, Livingston R, Johnson D et al. A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II non-small cell lung cancer (NSCLC). Intergroup JBR 10. N Engl J Med 2005; 352: 2589-97.
30. Arriagada R, Bergman B, Dunant A et al. Cisplatin based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-60.
31. Douillard J, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association[ANITA]): A randomized control trial. Lancet Oncol 2006; 7: 719-27.
32. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al. A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-21.
33. Tsuboi M, Ohira T, Saji H et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007; 13: 73-7.